試す金 - 無料

BioSpectrum Asia - September 2023

Magzter GOLDで無制限に

読む BioSpectrum Asia 9,500以上の雑誌や新聞を1回の定期購読で購読できます

カタログを見る

1ヶ月

$14.99

1年 $149.99

$149.99

$12/month

(OR)

BioSpectrum Asiaのみを購読する

贈り物 BioSpectrum Asia

いつでもキャンセルできます。

(義務なし) ⓘ

定期購読にご満足いただけない場合は、定期購読開始日から 7 日以内に help@magzter.com までメールをお送りいただければ、全額返金いたします。質問は一切ありません。お約束します! (注: 単号購入には適用されません)

デジタルサブスクリプション

即時アクセス ⓘ

今すぐ購読すると、Magzter の Web サイト、iOS、Android、Amazon アプリですぐに読み始めることができます。

安全性を確認済み

支払い ⓘ

Magzter は Authorize.Net の認定販売業者です。詳細はこちら

この号では

Multipronged Approach Against Alzheimer’s Disease
In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer’s drug Leqembi (lecanemab-irmb). This drug is the first to target the disease’s progression rather than merely addressing its symptoms. The approval has infused excitement and hope into the field of Alzheimer’s drug development, known for frequent drug failures. Alzheimer’s Disease (AD) is an escalating global health crisis. In 2020, the World Health Organisation (WHO) noted over 50 million people had dementia worldwide; 60 per cent of them lived in low- to middle-income countries. The Asia Pacific region bears a hefty burden with dementia care costs at $185 billion, straining healthcare in populous economies, according to ADI (Alzheimer’s Disease International). As we mark World Alzheimer’s Day this year on September 21, let’s take a stock of the advancements in the research and development in the Asia Pacific.

Multipronged Approach Against Alzheimer's Disease

In July 2023, Eisai and Biogen received full traditional approval from the United States Food and Drug Administration (US FDA) for their Alzheimer's drug Leqembi (lecanemab-irmb). This drug is the first to target the disease's progression rather than merely addressing its symptoms.

10+ mins

South Korea poised to become MEDICAL AI POWERHOUSE

When it comes to Al (Artificial Intelligence) in medical sciences - China and the USA dominate the field. However, South Korea has been steadily catching up. Home to renowned tech giants such as Samsung and LG Electronics, South Korea is positioning itself as a significant player in the medical Al domain. The country is making remarkable strides in deploying Al for medical imaging, diagnostics, drug development and healthcare. Let's look at South Korea's efforts in becoming a medical Al powerhouse.

7 mins

"We need concerted action that brings together everyone's work to solve the CVD crisis"

In June 2023, the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was established to address the increasing burden of cardiovascular disease in the region.

2 mins

"The APAC market is expected to witness the fastest growth of any radiopharmaceutical market worldwide"

Australian firm Telix Pharmaceuticals is pioneering advanced radiopharmaceuticals. Recently, the company achieved remarkable success with the global launch of Illuccix, their first commercial product for prostate cancer imaging in 2022.

8 mins

"Policies that help to add value to the R&D ecosystem are essential to empower Indian medical device sector"

OMRON Healthcare Manufacturing India (a subsidiary of OMRON Healthcare Corporation Japan) has begun the construction of its new plant in Chennai in May 2023.

5 mins

Regulatory Landscape of In Vitro Fertilisation (IVF) Across Asia

According to the World Health Organisation (WHO) data, approximately one in every six couples worldwide is impacted by infertility.

5 mins

Understanding Medicinal Drug Delivery Using Dry Powder Inhalers (DPIS)

For a long time, dry powder inhalers (DPI) have been used for treating asthma, and other respiratory diseases, by delivering medication directly to the lungs.

5 mins

BIO Asia-Taiwan 2023 attracts 100,000 visitors from 31 countries

The Taiwan Bio Industry Organization (Taiwan BIO) and the global Biotechnology Innovation Organisation (BIO) ignited Taiwan’s three-day conference BIO Asia-Taiwan 2023 from July 26 to 30 at the Taipei Nangang International Exhibition Center (TaiNEX 1 and TaiNEX 2).

6 mins

Sirnaomics brings Dr Francois Lebel on board for clinical development

With presence in both US and China, Sirnaomics has announced that Dr Francois Lebel, an experienced biopharmaceutical industry executive, has been appointed as Senior Vice President for preclinical and clinical development of the Group.

1 mins

South Korea offers customised treatment for lung cancer patients

A group of researchers at Pohang University of Science and Technology (POSTECH) in South Korea, along with researchers at Gradiant Bioconvergence, has recreated the internal environment of a lung cancer patient using a hydrogel derived from decellularised extracellular matrix (LudECM) obtained from porcine lungs.

1 mins

すべてのストーリーを読む BioSpectrum Asia

BioSpectrum Asia Description:

出版社: MM-Activ-Sci-Tech-Communication

カテゴリ: Business

言語: English

頻度: Monthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.

* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.

* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.

* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.

* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.